000169289 001__ 169289
000169289 005__ 20240229133647.0
000169289 0247_ $$2doi$$a10.1093/gerona/glaa128
000169289 0247_ $$2pmid$$apmid:32459845
000169289 0247_ $$2ISSN$$a1079-5006
000169289 0247_ $$2ISSN$$a1758-535X
000169289 0247_ $$2altmetric$$aaltmetric:82949893
000169289 037__ $$aDKFZ-2021-01386
000169289 041__ $$aEnglish
000169289 082__ $$a570
000169289 1001_ $$0P:(DE-He78)ad44271ecf6b1eec3e0d0089c66dfdbe$$aChen, Li-Ju$$b0$$eFirst author$$udkfz
000169289 245__ $$aSystematic Review and Meta-Analysis on the Associations of Polypharmacy and Potentially Inappropriate Medication With Adverse Outcomes in Older Cancer Patients.
000169289 260__ $$aOxford [u.a.]$$bOxford Univ. Pr.$$c2021
000169289 3367_ $$2DRIVER$$aarticle
000169289 3367_ $$2DataCite$$aOutput Types/Journal article
000169289 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1637159680_23141$$xReview Article
000169289 3367_ $$2BibTeX$$aARTICLE
000169289 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000169289 3367_ $$00$$2EndNote$$aJournal Article
000169289 500__ $$aC070#LA:C070#
000169289 520__ $$aBoth polypharmacy and potentially inappropriate medication (PIM) intake are highly prevailing in older cancer patients. However, only studies on the association of polypharmacy and postoperative complications have been meta-analyzed previously.A systematic review and a meta-analysis of prospective/retrospective observational studies reporting associations of polypharmacy or PIM with at least one out of five predefined adverse health outcomes in a population of older cancer patients (≥60 years) were carried out. PubMed and Web of Science were used to search for relevant studies published between January 1991 and March 2020. Data were pooled by adopting a random-effects model.Overall, 42 publications were included in the systematic review. Meta-analyses could be performed on 39 studies about polypharmacy and 13 studies about PIM. Polypharmacy was found to be statistically significantly associated with all-cause mortality (risk ratio [95% confidence interval]: 1.37 [1.25-1.50]), hospitalization (1.53 [1.37-1.71]), treatment-related toxicity (1.22 [1.01-1.47]), and postoperative complications (1.73 [1.36-2.20]). The association of polypharmacy with prolongation of hospitalization was not statistically significant at the p < .05 significance level (1.62 [0.98-2.66]). With respect to PIM, a statistically significant association with all-cause mortality (1.43 [1.08-1.88]) was observed but not with other adverse outcomes.Polypharmacy was found to be associated with several adverse outcomes and PIM use with all-cause mortality in older cancer patients. However, these results should be interpreted with caution because about three-quarters of the studies identified did not adjust for comorbidity and are prone to confounding by indication.
000169289 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000169289 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000169289 650_7 $$2Other$$aAdverse drug reaction
000169289 650_7 $$2Other$$aGeriatric oncology
000169289 650_7 $$2Other$$aHospitalizations
000169289 650_7 $$2Other$$aMortality
000169289 650_7 $$2Other$$aPostoperative complications
000169289 7001_ $$0P:(DE-He78)b09508a4c4afe85c57dd131eefa689ea$$aTrares, Kira$$b1$$udkfz
000169289 7001_ $$0P:(DE-He78)358cd16fe1dd16be6e4eaf0e76e5ad57$$aLaetsch, Dana Clarissa$$b2$$udkfz
000169289 7001_ $$0P:(DE-He78)abb10265fc5b7b424eee557e979d490f$$aNguyen, Thi Ngoc Mai$$b3$$udkfz
000169289 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b4$$udkfz
000169289 7001_ $$0P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aSchöttker, Ben$$b5$$eLast author$$udkfz
000169289 773__ $$0PERI:(DE-600)2043927-1$$a10.1093/gerona/glaa128$$gVol. 76, no. 6, p. 1044 - 1052$$n6$$p1044 - 1052$$tThe journals of gerontology / A$$v76$$x1758-535X$$y2021
000169289 909CO $$ooai:inrepo02.dkfz.de:169289$$pVDB
000169289 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ad44271ecf6b1eec3e0d0089c66dfdbe$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000169289 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b09508a4c4afe85c57dd131eefa689ea$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000169289 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)358cd16fe1dd16be6e4eaf0e76e5ad57$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000169289 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)abb10265fc5b7b424eee557e979d490f$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000169289 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000169289 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000169289 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000169289 9130_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000169289 9141_ $$y2021
000169289 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2021-01-28$$wger
000169289 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-01-28
000169289 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2021-01-28
000169289 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-01-28
000169289 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2021-01-28
000169289 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-28
000169289 915__ $$0StatID:(DE-HGF)0130$$2StatID$$aDBCoverage$$bSocial Sciences Citation Index$$d2021-01-28
000169289 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-28
000169289 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-01-28
000169289 915__ $$0StatID:(DE-HGF)1180$$2StatID$$aDBCoverage$$bCurrent Contents - Social and Behavioral Sciences$$d2021-01-28
000169289 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ GERONTOL A-BIOL : 2019$$d2021-01-28
000169289 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-01-28
000169289 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2021-01-28
000169289 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2021-01-28
000169289 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bJ GERONTOL A-BIOL : 2019$$d2021-01-28
000169289 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000169289 980__ $$ajournal
000169289 980__ $$aVDB
000169289 980__ $$aI:(DE-He78)C070-20160331
000169289 980__ $$aUNRESTRICTED